A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib (Q34180815)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib |
scientific article |
Statements
1 reference
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib (English)
1 reference
Pasi A Jänne
1 reference
D Ross Camidge
1 reference
Shirish M Gadgeel
1 reference
Fadlo R Khuri
1 reference
Jeff A Engelman
1 reference
Marianna Koczywas
1 reference
Arun Rajan
1 reference
Alicyn K Campbell
1 reference
Diana Gernhardt
1 reference
Stephen Letrent
1 reference
Jane Liang
1 reference
Ian Taylor
1 reference
Joseph P O'Connell
1 reference
5 February 2014
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference